< Back to search
Filter
1

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

for
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma,
Location: Boston MA, Philadelphia PA, Charlottesville VA,
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 18+

Code: NCT04104776

Phase1, Phase2, Recruiting

A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer

for
Metastatic Castration-Resistant Prostatic Cancer
Location: Toronto
Sponsor: T.O.A.D. Oncology SA

Sex: Male

Age: 18+

Code: NCT07258407

Phase1, Phase2, Recruiting

Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC

for
Metastatic Castration-resistant Prostate Cancer
Location: Tampa FL
Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Sex: Male

Age: 18+

Code: NCT07476001

Phase2, Recruiting

A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

for
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Location: Montreal, Dallas TX
Sponsor: Novartis Pharmaceuticals

Sex: Male

Age: 18+

Code: NCT07570979

Phase1, Recruiting

Total Body PET-CT Imaging of Prostate Cancer Using Illuccix

for
Metastatic Castration-resistant Prostate Cancer
Location: Grand Rapids MI
Sponsor: BAMF Health

Sex: Male

Age: 18+

Code: NCT05558956

Early_phase1, Recruiting

Interested in new castration-resistant prostate cancer trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

A Study of MGC026 in Participants With Advanced Solid Tumors

for
Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer,
Location: Lake Success NY, Grand Rapids MI, Houston TX,
Sponsor: MacroGenics

Sex: All

Age: 18+

Code: NCT06242470

Phase1, Recruiting

Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy

for
Castration-Resistant Prostate Carcinoma,
Location: Los Angeles CA
Sponsor: Jonsson Comprehensive Cancer Center

Sex: Male

Age: 0+

Code: NCT05398302

Phase1, Recruiting

Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial

for
Castration-Resistant Prostate Carcinoma,
Location: Los Angeles CA
Sponsor: Jonsson Comprehensive Cancer Center

Sex: Male

Age: 0+

Code: NCT06288113

Phase2, Recruiting

A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer

for
Prostatic Neoplasms, Castration-Resistant
Location: East Hanover NJ
Sponsor: Novartis Pharmaceuticals

Sex: Male

Age: 18 - 70+

Code: NCT07677254

Recruiting

A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan

for
Prostatic Neoplasms, Castration-Resistant
Location: East Hanover NJ
Sponsor: Novartis Pharmaceuticals

Sex: Male

Age: 18 - 70+

Code: NCT07677267

Recruiting

Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)

for
Prostate Carcinoma,
Location: Los Angeles CA
Sponsor: Jonsson Comprehensive Cancer Center

Sex: Male

Age: 18+

Code: NCT06216249

Phase2, Recruiting